PXS-4728 by Syntara for Sleep Disorders: Likelihood of Approval

PXS-4728 is under clinical development by Syntara and currently in Phase II for Sleep Disorders.

Excess sodium intake may increase the risk of eczema flares

UCSF study finds that changes in daily salt intake may explain eczema flares.

June 5, 2024

JTE-162 by Japan Tobacco for Inflammation: Likelihood of Approval

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes

September 14, 2023

Zeus Launches Next-Generation Tubing for Bioresorbable Vascular Scaffolds

September 27, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.